Epilepsy Research
Volume 29, Issue 3 , Pages 233-249 , February 1998

A summary of mechanistic hypotheses of gabapentin pharmacology

  • Charles P Taylor

      Affiliations

    • Department of Neuroscience Therapeutics, Parke–Davis Pharmaceutical Research, Division of Warner–Lambert Co., Ann Arbor, MI 48105, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Nicolas S Gee

      Affiliations

    • Parke–Davis Neuroscience Research Centre, Cambridge University Forvie Site, Robinson Way, Cambridge, CB2 2QB, UK
    • ,
  • Ti-Zhi Su

      Affiliations

    • Department of Molecular Biology, Parke–Davis Pharmaceutical Research, Division of Warner–Lambert Co., Ann Arbor, MI 48105, USA
    • ,
  • Jeffery D Kocsis

      Affiliations

    • Neuroscience and Regeneration Research Center A127A, Veterans Affairs Medical Center, Building 34, Room 123, 950 Campbell Ave., West Haven, CT 06516, USA
    • ,
  • Devin F Welty

      Affiliations

    • Department of Pharmacokinetics and Drug Metabolism, Parke–Davis Pharmaceutical Research, Division of Warner–Lambert Co., Ann Arbor, MI 48105, USA
    • ,
  • Jason P Brown

      Affiliations

    • Parke–Davis Neuroscience Research Centre, Cambridge University Forvie Site, Robinson Way, Cambridge, CB2 2QB, UK
    • ,
  • David J Dooley

      Affiliations

    • Department of Neuroscience Therapeutics, Parke–Davis Pharmaceutical Research, Division of Warner–Lambert Co., Ann Arbor, MI 48105, USA
    • ,
  • Philip Boden

      Affiliations

    • Parke–Davis Neuroscience Research Centre, Cambridge University Forvie Site, Robinson Way, Cambridge, CB2 2QB, UK
    • ,
  • Lakhbir Singh

      Affiliations

    • Parke–Davis Neuroscience Research Centre, Cambridge University Forvie Site, Robinson Way, Cambridge, CB2 2QB, UK

Received 28 July 1997 ,Revised 1 October 1997 ,Accepted 8 October 1997.

References 

  1. Andrews J, Chadwick D, Bates D. Gabapentin in partial epilepsy. Lancet. 1990;335:1114–1117
  2. Backonja, M., Hes, M.S., LaMoreaux, L.K., Garofalo, E.A., Koto, E.M. and the US Gabapentin Study Group 210, 1997. Gabapentin reduces pain in diabetics with painful peripheral neuropathy: results of a double-blind, placebo-controlled clinical trial (945-210) [Abstract], American Pain Society, 16th Annual Meeting, Abstracts, p. 108.
  3. Bartoszyk, G.D., Meyerson, N., Reimann, W., Satzinger, G., von Hodenberg, A., 1986. Gabapentin. In: Meldrum, B.S., Porter, R.J. (Eds.). New Anticonvulsant Drugs. John Libbey, London, pp. 147–163.
  4. Beydoun A, Fischer J, Labar DR, Harden C, Cantrell D, Uthman BM, et al. Gabapentin monotherapy: II. A 26-week double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex-partial or secondarily generalized seizures. Neurology. 1997;49:746–752
  5. Bloms-Funke P, Löscher W. The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons. Eur. J. Pharmacol. 1996;316:211–218
  6. Bowery NG. GABA-B receptor pharmacology. Annu. Rev. Pharmacol. Toxicol. 1993;33:109–147
  7. Brickley K, Campbell V, Berrow N, Leach R, Norman RI, Wray D, et al. Use of site-directed antibodies to probe the topography of the α2 subunit of voltage-gated Ca2+ channels. FEBS Lett. 1995;364:129–133
  8. Broekkamp CL, Berendsen HH, Jenck F, VanDelft AM. Animal models for anxiety and response to serotonergic drugs. Psychopathology. 1989;22:2–21
  9. Burgey GK, Morris HH, Rosenfeld W, Blume WT, Penovich PE, Morrell MJ, et al. Gabapentin monotherapy: I. An 8-day double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex-partial or secondarily generalized seizures. Neurology. 1997;49:739–745
  10. Catterall WA. Structure and function of voltage-gated ion channels. Ann. Rev. Biochem. 1995;64:493–531
  11. DeJongh KS, Warner C, Catterall WA. Subunits of purified calcium channels: α2 and δ are encoded by the same gene. J. Biol. Chem. 1990;265:14738–14741
  12. Dolphin AC. Voltage-dependent calcium channels and their modulation by neurotransmitters and G-proteins. Exp. Physiol. 1995;80:1–36
  13. Dooley DJ, Suman-Chauhan N, Madden Z. Inhibition of K+-evoked [3H]noradrenaline release from rat neocortical slices by the anticonvulsant gabapentin [abstract]. Soc. Neurosci. Abstr. 1996;22:1992
  14. Dubuisson D, Dennis SG. The formalin test: a quantitative study of analgesic effects of morphine, meperidine, and brain stem stimulation on rats and cats. Pain. 1977;4:161–174
  15. During M, Ryder KM, Spencer DD. Hippocampal GABA transporter function in temporal-lobe epilepsy. Nature. 1995;376:174–177
  16. Ellis SB, Williams ME, Ways NR, Brenner R, Sharp AH, Leung AT, et al. Sequence and expression of mRNAs encoding the α1 and α2 subunits of a DHP-sensitive calcium channel. Science. 1988;241:1661–1664
  17. Erlander MG, Tobin AJ. The structural and functional heterogeneity of glutamic acid decarboxylase: A review. Neurochem. Res. 1991;16:215–226
  18. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron. 1991;7:91–100
  19. Everhart AW, Willis WD, Hulsebosch CE. Gabapentin inhibits mechanical and thermal allodynia in a rodent model of chronic central pain following spinal hemisection [abstract]. Soc. Neurosci. Abstr. 1997;23:1812
  20. Fichter N, Taylor CP, Feuerstein TJ. Nipecotate-induced GABA release from slices of the rat caudato-putamen: effects of gabapentin N–S [abstract]. Arch. Pharmacol. 1996;354:R35
  21. Field MJ, Holloman EF, McCleary S, Hughes J, Singh L. Evaluation of gabapentin and S-(+)-3-isobutylGABA in a rat model of postoperative pain. J. Pharmacol. Exp. Ther. 1997;282:1242–1246
  22. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (Neurontin) and S-(+)-3-isobutyl GABA represent a novel class of selective antihyperalgesic agents. Br. J. Pharmacol. 1997;121:1513–1522
  23. Foster AC, Fagg GE. Taking apart NMDA receptors. Nature. 1987;329:395–396
  24. Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem. 1996;271:5768–5776
  25. Gillin, S., Sorkin, L.S., 1997. Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic agent. Anesth. Analg. (in press).
  26. Goldlust A, Su T, Welty DF, Taylor CP, Oxender DL. Effects of the anticonvulsant drug gabapentin on enzymes in the metabolic pathways of glutamate and GABA. Epilepsy Res. 1995;22:1–11
  27. Götz E, Feuerstein TJ, Meyer DK. Effects of gabapentin on release of γ-aminobutyric acid from slices of rat neostriatum. Drug Res. 1993;43:636–638
  28. Gram L, Larsson OM, Johnsen A, Schousboe A. Experimental studies of the influence of vigabatrin on the GABA system. Br. J. Clin. Pharmacol. 1989;27:13S–18S
  29. Gurnett CA, DeWaard M, Campbell KP. Dual function of the voltage-dependent Ca2+ channel α2δ subunit in current stimulation and subunit interaction. Neuron. 1996;16:431–440
  30. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice expressing a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772–1775
  31. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996;39:147–157
  32. Hamilton SL, Hawkes MJ, Brush K, Cook R, Chang RJ, Smilowitz HM. Subunit composition of the purified dihydropyridine binding protein from skeletal muscle. Biochemistry. 1989;28:7820–7828
  33. Hargreaves KR, Dubner F, Brown C, Flores AS, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77–84
  34. Hill DR, Suman Chauhan N, Woodruff GN. Localization of [3H]-gabapentin to a novel site in rat brain: autoradiographic studies. Eur. J. Pharmacol. 1993;244:303–309
  35. Hofmann F, Biel M, Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu. Rev. Neurosci. 1994;17:399–418
  36. Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res. 1995;20:193–202
  37. Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res. 1995;692:273–277
  38. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur. J. Pharmacol. 1997;324:153–160
  39. Hutson SM, Drown P, I'lyosova D, Reinhart GD. Role of gabapentin and branched chain aminotransferase isoenzymes in astrocyte neurotransmitter metabolism [abstract]. J. Neurochem. 1995;66:S76
  40. Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically-induced neuropathic pain model in the rat. Reg. Anesthesia. 1997;22:249–256
  41. Jay SD, Sharp AH, Kahl SD, Vedvick TS, Harpold MM, Campbell KP. Structural characterization of the dihydropyridine-sensitive calcium channel α2-subunit and the associated δ peptides. J. Biol. Chem. 1991;266:3287–3293
  42. Jun, J.H., Yaksh, T.L., 1997. Effect of intrathecal gabapentin and 3-isobutyl GABA on the hyperalgesia observed after thermal injury in the rat. Anesth. Analg. (in press).
  43. Kapetanovic IM, Taylor CP, Yonekawa WD, Kupferberg HJ. Effect of gabapentin (GBP) on amino acids in rat hippocampal slices in vitro [abstract]. Soc. Neurosci. Abstr. 1995;21:2117
  44. Kawasaki H, Mattia D, Zona C, Avoli M. Effects induced by gabapentin on the electrophysiological properties of bursting neurons in the rat subiculum in vitro [abstract]. Soc. Neurosci. Abstr. 1995;21:2117
  45. Keynan S, Kanner BI. γ-aminobutyric acid transport in reconstituted preparations from rat brain: coupled sodium and chloride fluxes. Biochemistry. 1988;27:12–17
  46. Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci. Lett. 1994;169:181–184
  47. Kocsis JD, Mattson RH. GABA levels in the brain: a target for new antiepileptic drugs. Neuroscientist. 1996;2:326–334
  48. Leach JP, Sills GJ, Butler E, Forrest G, Thompson GG, Brodie MJ. Neurochemical actions of gabapentin in mouse brain. Epilepsy Res. 1997;27:175–180
  49. Leung AT, Imagawa T, Block B, Franzini-Armstrong C, Campbell KP. Biochemical and ultrastructural characterization of the 1,4-dihydropyridine receptor from rabbit skeletal muscle. Evidence for a 52 000 Da subunit. J. Biol. Chem. 1988;263:994–1001
  50. Liron Z, Wong E, Roberts E. Studies on uptake of γ-aminobutyric acid by mouse brain particles; toward the development of a model. Brain Res. 1988;444:119–132
  51. Löscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett. 1991;128:150–154
  52. Macdonald RL, Olsen RW. GABAA receptor channels. Annu. Rev. Neurosci. 1994;17:569–602
  53. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability [see comments]. Br. Med. J. 1996;313:1169–1174
  54. Martin D, Martin SB, Wu SJ, Espina N. Regulatory properties of brain glutamate decarboxylase (GAD): The apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain. J. Neurochem. 1991;11:2725–2731
  55. Mattson RH, Rothman DL, Behar KL, Petroff OAC. Gabapentin: a GABA active drug [abstract]. Epilepsia. 1997;38:65–66
  56. McCall WD, Tanner KD, Levine JD. Formalin induces biphasic activity in C-fibers in the rat. Neurosci. Lett. 1996;208:45–48
  57. McGraw T, Kosek P. Erythromelalgia pain managed with gabapentin. Anesthesiol. 1997;86:988–990
  58. McLean, M.J., 1995. Gabapentin: chemistry, absorption, distribution and excretion. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs. Raven, New York, pp. 843–849.
  59. McLean MJ, Ramsey RE, Leppik I, Rowan AJ, Shellenberger MK, Wallace J, et al. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology. 1993;43:2292–2298
  60. Meldrum, B.S., 1985. GABA and other amino acids. In: Frey, M.M., Janz, D. (Eds.), Antiepileptic Drugs. Springer, Berlin, pp. 153–188.
  61. Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. Arch. Phys. Med. Rehabil. 1997;78:98–105
  62. Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J. Pain Symptom Manage. 1995;10:265–266
  63. Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 1996;47:1383–1388
  64. Mori Y, Freidrich T, Kim MS, Mikami A, Nakai J, Ruth P, et al. Primary structure and functional expression from complimentary DNA of a brain calcium channel. Nature. 1991;350:398–402
  65. Ochi S, Lim JY, Rand MN, During MJ, Sakatani K, Kocsis JD. Transient presence of GABA in astrocytes of the developing optic nerve. Glia. 1993;9:188–198
  66. Paslawski T, Treit D, Baker GB, George M, Coutts RT. The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA. Psychopharmacology. 1996;127:19–24
  67. Perez-Reyes E, Schneider T. Calcium channels: structure, function and classification. Drug Devl. Res. 1994;33:295–318
  68. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann. Neurol. 1996;39:95–99
  69. Petroff, O.A., Manor, D., Behar, K.L., 1997. Gabapentin decreases cortical glutamate rapidly in a rat model. Epilepsy Res. (submitted).
  70. Pin JP, Bockaert J. Two distinct mechanisms, differentially affected by excitatory amino acids, trigger GABA release from fetal mouse striatal neurons in primary culture. J. Neurosci. 1989;9:648–656
  71. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: A hypothesis. Ann. Neurol. 1990;28:3–8
  72. Pragnall M, De Waard M, Mori Y, Tanabe T, Snutch TP, Campbell KP. Calcium channel β subunit binds to a conserved motif in the I–II cytoplasmic linker of the α1-subunit. Nature. 1994;368:67–70
  73. Pugsley, T.A., Whetzel, S.Z., Dooley, D.J., 1997. Reduction of 3,4-diaminopyrdine-induced biogenic amine synthesis and release in rat brain by gabapentin. Psychopharmacol. (in press).
  74. Ramsey, R.E., 1995. Gabapentin: toxicity. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs. Raven Press, New York, pp. 857–860.
  75. Rao ML, Clarenbach P, Vahlensieck M, Kraetzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J. Neural. Transm. 1988;73:129–134
  76. Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action?. Eur. J. Pharmacol. 1983;94:341–344
  77. Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res. 1993;16:89–98
  78. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin. J. Pain. 1996;12:56–58
  79. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J. Neurochem. 1995;65:643–651
  80. Satzinger G. Antiepileptics from γ-aminobutyric acid. Drug Res. 1994;44:261–266
  81. Sayin U, Rutecki PA, Mellanby J, Sutula TP. γ-vinyl GABA impairs paired pulse inhibition in the rat dentate gyrus in vivo and in vitro [abstract]. Epilepsia. 1997;38(Suppl. 8):110–111
  82. Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Drug Res. 1985;35:1347–1349
  83. Schumacher, T.B., Beck, H., Steinhauser, C., Schramm, J., Elger, C.E., 1997. Effects of gabapentin, phenytoin and carbamazepine on calcium currents in hippocampal granule cells from patients with temporal lobe epilepsy. Epilepsia (in press).
  84. Sharp AH, Campbell KP. Characterization of the 1,4-dihydropyridine receptor using subunit-specific polyclonal antibodies. Evidence for a 32 000-Da subunit. J. Biol. Chem. 1989;264:2816–2825
  85. Shistik E, Ivanina T, Puri T, Hosey M, Dascal N. Ca2+ current enhancement by α2-δ and β subunits in Xenopus oocytes: Contribution of changes in channel gating and α1 protein level. J. Physiol. 1995;489:55–62
  86. Singer D, Biel M, Lotan I, Flockerzi V, Hofmann F, Dascal N. The roles of the subunits in the function of the calcium channel. Science. 1991;253:1553–1557
  87. Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, et al. The behavioral properties of CI-988, a selective cholesystokininB receptor antagonist. Br. J. Pharmacol. 1991;104:239–245
  88. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by d-serine. Psychopharmacology. 1996;127:1–10
  89. Stefani, A., Spadoni, F., Bernardi, G., 1997. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology (submitted).
  90. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharmaceut. Res. 1993;10:276–281
  91. Stewart BH, Reyner EL, Lu RH. Mechanism of gabapentin (Neurontin) transport across monolayers of human colon adenocarcinoma cells (CACO-2). Amino Acids. 1993;5:204–205
  92. Su T, Lunney E, Campbell G, Oxender DL. Transport of gabapentin, a γ-amino acid drug, by system L a-amino acid transporters: a comparative study in astrocytes, synaptosomes and CHO cells. J. Neurochem. 1995;64:2125–2131
  93. Suman Chauhan N, Webdale L, Hill DR, Woodruff GN. Characterisation of [3H]-gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur. J. Pharmacol. 1993;244:293–301
  94. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 1995;36:612–626
  95. Suzdak PD, Foged C, Andersen KE. Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res. 1994;647:231–241
  96. Szerb, J.C., 1982. Effect of nipecotic acid, a γ-aminobutyric acid transport inhibitor, on the turnover and release of γ-aminobutyric acid in rat cortical slices. J. Neurochem. 850–858.
  97. Tapia R, Salazar P. Glutamate decarboxylase activity in the substantia nigra and the hippocampus of rats microinjected with inhibitors of the enzyme. Neurochem. Res. 1991;16:263–267
  98. Taylor CP. The anticonvulsant lamotrigine blocks sodium currents from cloned α-subunits of rat brain Na+ channels in a voltage-dependent manner but gabapentin does not. Soc. Neurosci. Abstr. 1993;23:1631
  99. Taylor, C.P., 1995. Gabapentin: Mechanisms of Action. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs. Raven Press, New York, pp. 829–841.
  100. Taylor CP, Vartanian MG, Andruszkiewiewicz R, Silverman RB. 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res. 1992;11:103–110
  101. Taylor CP, Vartanian MG, Yuen P, Bigge C, Suman Chauhan N, Hill DR. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 1993;14:11–15
  102. Thurlow RJ, Brown JP, Gee NS, Hill DR, Woodruff GN. [3H]-gabapentin binding may label a system-L like neutral amino acid carrier in brain. Eur. J. Pharmacol. 1993;247:341–345
  103. Tunnicliff, G., Raess, B.U., 1991. GABA Mechanisms in Epilepsy. Wiley Liss, New York, p. 218.
  104. Vollmer KO, vonHodenberg A, Koelle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneim. Forsch. Drug Res. 1986;36:830–839
  105. Wamill AW, McLean MJ. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res. 1994;17:1–11
  106. Welty DF, Schielke GP, Vartanian MG, Taylor CP. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentration in plasma and brain microdialysate. Epilepsy Res. 1993;16:175–181
  107. Welty DF, Schielke GP, Rothstein JD. Potential treatment of amyotrophic lateral sclerosis by the anticonvulsant gabapentin: A hypothesis. Ann. Pharmacother. 1995;29:1164–1167
  108. Welty DF, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL. Pharmacokinetics and pharmacodynamics of CI-1008 (pregabalin) and gabapentin in rats using maximal electroshock [abstract]. Epilepsia. 1997;38(Suppl. 8):35–36
  109. Wheeler-Aceto H, Porreca F, Cowan A. The rat paw formalin test: comparison of noxious agents. Pain. 1990;40:229–238
  110. Williams ME, Brust PF, Feldman DH, Patthi S, Simerson S, Maroufi A, et al. Structure and functional expression of an omega-conotoxin- sensitive human N-type calcium channel. Science. 1992;257:389–395
  111. Witcher DR, De Waard M, Sakamoto J, Franzini-Armstrong C, Pragnell M, Kahl SD, et al. Subunit identification and reconstitution of the N-type Ca2+ channel complex purified from brain. Science. 1993;261:486–489
  112. Woolf CJ, Wall PD. Relative effectiveness of C-primary afferent fibers of different origins in evoking a prolonged facilitation of the flexor reflex in the rat. J. Neurosci. 1986;6:1433–1442
  113. Xiao, W.-H., Bennett, G.J., 1997. Gabapentin relieves abnormal pain sensations via a spinal site of action in a rat model of painful peripheral neuropathy. Pain in press.
  114. Xiong Z-Q, Stringer JL. Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. Epilepsy Res. 1997;27:187–194

PII: S0920-1211(97)00084-3

Epilepsy Research
Volume 29, Issue 3 , Pages 233-249 , February 1998

Article Tools

* Image Usage & Resolution